Synthesis and Preliminary Biological Evaluation of Indol-3-yl-oxoacetamides as Potent Cannabinoid Receptor Type 2 Ligands
Helmholtz-Zentrum Dresden-Rossendorf e.V., Institute of Radiopharmaceutical Cancer Research, Permoserstr. 15, 04318 Leipzig, Germany; w.deuther-conrad@hzdr.de (W.D.-C.); p.brust@hzdr.de (P.B.)
Johns Hopkins School of Medicine, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Baltimore, MD 21287, USA; ahorti1@jhmi.edu
Abstract
A small series of indol-3-yl-oxoacetamides was synthesized starting from the literature known N-(adamantan-1-yl)-2-(5-(furan-2-yl)-1-pentyl-1H-indol-3-yl)-2-oxoacetamide (5) by substituting the 1-pentyl-1H-indole subunit. Our preliminary biological evaluation showed that the fluorinated derivative 8 is a potent and selective CB2 ligand with Ki = 6.2 nM.
Untitled section
Keywords: positron emission tomography, cannabinoid receptor type 2, binding affinity, indole
Article notes
Untitled section
Received 2016 Oct 21; Accepted 2016 Dec 22; Collection date 2017 Jan.
1. Introduction
For centuries, Cannabis sativa was used as medicinal plant for the treatment of pain and inflammatory processes. The discovery by Gaoni and Mechoulam [1] of Δ9-tetrahydrocannabinol (Δ9-THC)—the primary psychoactive ingredient in Cannabis sativa—set the stage for the identification of the endogenous cannabinoid (endocannabinoid) transmitter system in the brain. The endocannabinoid system consists of cannabinoid (CB) receptors, endogenous ligands (e.g., anandamide, 2-O-arachidonoylglycerol) that activate the CB receptors, and the enzymes, which are responsible for the biosynthesis (e.g., N-acyltransferase, diacylglycerol lipase) and deactivation (e.g., fatty acid amide hydrolases, monoacylglycerol lipases) of the endogenous ligands [2,3].
Two types of specific Gi/o-protein-coupled CB receptors were cloned in the 1990s, termed CB1 and CB2 receptor [4,5]. CB1 receptors are abundantly expressed in the central nervous system, and their function has been thoroughly investigated [6]. Recently, the crystal structure of the CB1 receptors has been reported, providing a tool for a more accurate pharmacological investigation of this receptor subtype [7,8]. In contrast to CB1 receptors, the CB2 receptor was originally regarded as a peripheral receptor predominantly expressed in cells of the immune system [5,9,10]. However, more recent investigations proved the presence of CB2 receptors in glial cells (microglia and astrocytes) [11,12], and oligodendroglial [13] progenitors in vitro, as well as in microglia [14] and neuronal progenitors [12] in normal mouse brain in vivo [15].
The predominant expression of the CB2 receptor in cells of the immune system suggests a modulation of diverse immune functions, including cytokine production, lymphocyte proliferation, and humoral and cell-mediated immune responses [16,17]. With respect to neuroinflammation, microglia adopt a key function. Under healthy conditions, the expression of CB2 receptors in the brain is rather low [18]. However, inflammatory effects result in considerably increased expression levels of CB2 receptors [19,20]. It was found that neurodegenerative and neuroinflammatory processes in the brain related to, for example, depression, Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain tumors such as glioblastoma are associated with an upregulation of CB2 receptor expression [18,21,22,23]. CB2 receptor agonists lead to a reduction of neuroinflammation and stimulation of neurogenesis. Therefore, the therapeutic potential of CB2 agonists is related to neurodegenerative and neuroinflammatory processes [19,24]. Moreover, the availability of CB2 receptors as measured with positron emission tomography (PET) [25] could potentially be used as a biomarker for neurodegenerative and neuroinflammatory processes in the brain [26,27,28,29].
Indole has been a very popular key building block for the medicinal chemistry of cannabinoid receptor ligands, and a large number of indole-derived CB2 selective ligands have been developed [30,31,32,33]. However, most of these ligands do not comply with the most important needs of a ligand suitable for the development of a tracer for CB2 brain imaging with PET; namely, high affinity towards CB2 (Ki(CB2) < 1 nM) and high selectivity over CB1 (Ki(CB2)/(CB1) > 500) [26,34]. Recently, we reported the development of a highly affine and selective 18F-labeled CB2 radiotracer (Ki(CB2) = 0.4 nM, Ki(CB1) = 380 nM), and proved its applicability in a mouse model of neuroinflammation [35]. However, this radioligand suffers from low metabolic stability in vivo, and therefore we redirected our focus on the structure of the literature known, highly affine N-(adamantan-1-yl)-2-(5-(furan-2-yl)-1-pentyl-1H-indol-3-yl)-2-oxoacetamide (5, Ki(CB2) = 0.37 nM and Ki(CB1) = 345 nM) [32] for the development of a CB2 radiotracer. In the present work, we show the synthesis and preliminary biological evaluation of fluorine-containing indol-3-yl-oxoacetamide derivatives.
2. Results and Discussion
The structure–affinity relationship study which lead to the identification of compound 5 [32,36] (Scheme 1) and the work performed on the structurally related quinolinone-3-carboxamides as CB2 ligands [37] has proven the importance of the substitution pattern at the 5-indole position, and also the need of the lipophilic adamantane subunit. Herein, we investigate the possibility of introducing a fluorine atom by modifying the alkyl chain at the indole 1-position.
The synthesis of the key building block 3 was performed as described in the literature [32] and depicted in Scheme 1. Treatment of 5-bromoindole (1) with oxalyl chloride delivered the corresponding indole-3-oxoacetyl chloride in ~60% yield, which was further reacted with amantadine (adamantan-1-amine) in presence of triethylamine (Et3N) to give compound 2. Next, Suzuki coupling was performed using the commercially available 2-furanboronic acid in presence of Pd(PPh3)4 and Na2CO3 to give 3. The lead molecule 5 [32] was synthesized by treating 3 with 1-bromobutane in basic reaction condition in ~25% yield over four steps starting from 1, as a light yellow solid. To overcome the high lipophilicity of the indole-N-alkyl chain [38], ether groups were introduced at this site of the molecule, and simultaneously, the influence of its length on the CB2 binding affinity was investigated. Thus, the glycol ether compound 6 was synthesized from 3 by using 2-(2-(2-fluoroethoxy)ethoxy)ethyl-4-methylbenzenesulfonate [39,40] as alkylating reagent in 72% yield. Similarly, alcohol 4 was synthesized by reacting compound 3 with 2-bromethanol. Alcohol 4 was further etherified via Williamson ether synthesis [41] by using methyl iodide and 2-fluoro-1-bromoethane to give compounds 7 and 8, respectively (for 1H-NMR of compounds 3, 5, 6, 7 and 8 see Supplementary Materials).
The binding affinity towards CB2 receptors was determined in vitro by radioligand inhibition binding assays according to a recently published protocol [42,43] using cell membranes from CHO cells stably transfected with the human CB2 (Prof Paul L. Prather, University Arkansas for Medical Sciences, Little Rock, AR, USA), [3H]WIN55.212-2 as competitive radioligand (KD = 2.1 nM) and increasing concentrations (100 pM to 10 µM) of compounds 5, 6, 7, and 8 added in triplicate for each experiment. Non-specific binding was determined using 10 µM WIN55.212-2. The individual IC50 values were determined by non-linear curve fitting using GraphPad Prism software (version 3.0, GraphPhad, San Diego, CA, USA), and the corresponding Ki values calculated using the Cheng–Prusoff equation [44]. As shown by the Ki values in Figure 1b, we could not reproduce the reported sub-nanomolar CB2 affinity of the lead molecule (compound 5) [32], but recorded a Ki value of 8.5 nM instead. In addition, these values and the individual binding curves in Figure 1a illustrate that a similar low-nanomolar affinity was observed for the fluorinated derivative 8 (Ki = 6.2 nM), while slightly lower affinities were determined for compounds 6 and 7 (Ki = 27.3 nM, and Ki = 16.1 nM, respectively). Additionally, the binding affinities towards the CB1 receptor were investigated for compounds 6 and 8 by using [3H]CP55.40 as competitive radioligand. None of the two derivatives could displace [3H]CP55.40 from the human CB1 receptors up to a concentration of 100 µM. Thus, within this series of fluoro-substituted compounds, the N-alkyl chain of compound 8 is most suitable to obtain high affinity binding at the CB2 receptor, combined with an excellent selectivity against the CB1 receptor subtype.
3. Materials and Methods
3.1. General Methods
All reagents were used directly as obtained commercially, unless otherwise noted. Reaction progress was monitored by thin-layer chromatography (TLC) using silica gel 60 F254 (0.040–0.063 mm) with detection by UV. All moisture-sensitive reactions were performed under an argon atmosphere using oven-dried glassware and anhydrous solvents. Column flash chromatography was carried out using E. Merck silica gel 60F (230–400 mesh) (Merck Millipore, Darmstadt, Germany). Analytical TLC was performed on aluminum sheets coated with silica gel 60 F254 (0.25 mm thickness, E. Merck, Darmstadt, Germany). 1H-NMR spectra were recorded with a Bruker-400 NMR spectrometer (Bruker, Billerica, MA, USA) at nominal resonance frequencies of 400 MHz, in CDCl3 or DMSO-d6 (referenced to internal Me4Si at δH 0 ppm). The chemical shifts (δ) were expressed in parts per million (ppm). High resolution mass spectra were recorded utilizing electrospray ionization (ESI) at the University of Notre Dame Mass Spectrometry facility.
3.2. Procedures and Compound Characterization
N-(Adamantan-1-yl)-2-(5-(furan-2-yl)-1-(2-hydroxyethyl)-1H-indol-3-yl)-2-oxoacetamide (4). 2-bromethanol (55 µL, 1.2 eq, 0.77 mmol) was added to a solution of 3 (300 mg, 1 eq, 0.64 mmol) in 5 mL N,N-dimethylformamide (DMF) at room temperature, followed by powder KOH (116 mg, 3 eq, 1.93 mmol), and the reaction mixture was warmed to 90 °C for 6 h. Saturated aqueous NaHCO3 solution (15 mL) and ethyl acetate (EA, 15 mL) were added, and the phases were separated. The aqueous phase was washed 2 × EA (10 mL), the combined organic solutions were dried over MgSO4, filtered, and concentrated by rotary evaporation. The residue was purified by column chromatography (silica, EA:Hex, 1/1) to give alcohol 4 (224 mg, 67% yield) as yellow solid. 1H-NMR (400 MHz, CDCl3): δ (ppm) = 1.67–1.76 (m, 6H), 2.05–2.12 (m, 6H), 2.07–2.11 (m, 6H), 2.14 (br s, 3H), 2.41 (br s, 1H), 3.96–4.06 (t, J = 5.18 Hz, 2H), 4.31 (t, J = 5.18 Hz, 2H), 6.51 (dd, J = 3.28, 1.77 Hz, 1H), 6.71 (dd, J = 3.28, 0.76 Hz, 1H), 7.35 (s, 1H), 7.40 (dd, J = 8.59, 0.76 Hz, 1H), 7.50 (dd, J = 1.77, 0.76 Hz, 1H), 7.65 (dd, J = 8.59, 1.52 Hz, 1H), 8.71 (dd, J = 1.77, 0.51 Hz, 1H), 8.99–9.10 (m, 1H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 29.36 (3C), 36.29 (3C), 41.15 (3C), 49.58, 51.84, 61.26, 104.42, 110.40, 111.72, 112.16, 118.02, 120.29, 126.77, 128.24, 135.74, 141.77, 142.03, 154.59, 161.48, 181.14.
N-(Adamantan-1-yl)-2-(5-(furan-2-yl)-1-pentyl-1H-indol-3-yl)-2-oxoacetamide (5). This compound was obtained according to literature. 1H-NMR (400 MHz, CDCl3): δ (ppm) = 0.86–0.94 (m, 3H), 1.28–1.44 (m, 4H), 1.69–1.81 (m, 6H), 1.93 (quin, J = 7.33 Hz, 2H), 2.10–2.20 (m, 9H), 4.16 (t, J = 7.33 Hz, 2H), 6.51 (dd, J = 3.28, 1.77 Hz, 1H), 6.73 (dd, J = 3.28, 0.76 Hz, 1H), 7.37–7.44 (m, 2 H), 7.50 (dd, J = 1.89, 0.63 Hz, 1H), 7.69 (dd, J = 8.59, 1.77 Hz, 1H), 8.73–8.78 (m, 1H), 9.04 (s, 1H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 13.94, 22.29, 28.99, 29.38 (3C), 29.60, 36.32 (3C), 41.21 (3C), 47.58, 51.78, 104.35, 110.43, 111.70, 111.91, 118.10, 120.13, 126.67, 128.36, 135.60, 141.62, 141.74, 154.70, 161.58, 180.97.
N-(Adamantan-1-yl)-2-(1-(2-(2-(2-fluoroethoxy)ethoxy)ethyl)-5-(furan-2-yl)-1H-indol-3-yl)-2-oxoacetamide (6). 2-(2-(2-fluoroethoxy)ethoxy)ethyl-4-methylbenzenesulfonate (40 mg, 1.5 eq, 0.15 mmol) and KOH (25 mg, 5 eq, 0.5 mmol) were added at room temperature to a solution of compound 3 (46 mg, 1 eq, 0.1 mmol) in 3 mL DMF, and the reaction mixture was warmed to 90 °C for 6 h. To the cooled down solution, 15 mL saturated aqueous NaHCO3 solution was added followed by 15 mL EA. The phases were separated, and the aqueous phase was separated 2 × 10 mL EA. The combined organic phases were washed with 20 mL brine, dried over MgSO4, and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica, EA:Hex, 1/1) to give 6 (44 mg, 72% yield) as yellow solid. 1H-NMR (400 MHz, CDCl3): δ (ppm) = 1.68–1.79 (m, 6H), 2.08–2.19 (m, 9H), 3.51–3.71 (m, 6H), 3.65–3.70 (m, 2H), 3.90 (t, J = 5.43 Hz, 2H), 4.37 (t, J = 5.43 Hz, 2H), 4.40–4.45 (m, 1H), 4.49–4.68 (m, 1 H), 6.51 (dd, J = 3.28, 1.77 Hz, 1H), 6.72 (dd, J = 3.28, 0.76 Hz, 1H), 7.38 (s, 1H), 7.41–7.54 (m, 2H), 7.69 (dd, J = 8.59, 1.77 Hz, 1H), 8.69–8.88 (m, 1H), 9.08 (s, 1H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 29.38 (3C), 36.32 (3C), 41.20 (3C), 47.43, 51.76, 69.66 (2C), 70.43, 70.62, 70.81, 71.02 (2C), 83.95, 104.37, 110.64, 111.70, 117.98, 120.15, 126.69, 128.21, 135.84, 141.76, 142.29, 181.21. HRMS (ESI+): m/z (%) = 523.6150 (ccd. 523.6151) [M + H]+.
N-(Adamantan-1-yl)-2-(5-(furan-2-yl)-1-(2-methoxyethyl)-1H-indol-3-yl)-2-oxoacetamide (7). NaH (60% suspension in mineral oil, 10 mg, 2 eq, 0.25 mmol) was added to a solution of 4 (65 mg, 1 eq, 1.12 mmol) in 2 mL DMF at 0 °C, and the mixture was stirred at 0 °C for 15 min. MeI (64 µL, 8 eq, 1.02 mmol) was added, the ice bath was removed, and the reaction was magnetically stirred at room temperature. After 5 h, the reaction was quenched by slow addition of 2 mL cold water followed by 10 mL saturated aqueous NaHCO3 solution and 15 mL EA. The phases were separated, and the aqueous phase was washed three times with 10 mL EA. The combined organic phases were washed with brine, dried over MgSO4, and concentrated under reduced pressure. The resulting material was purified by column chromatography (silica, EA:Hex, 1/1) to give 7 (55 mg, 84% yield), yellow solid. 1H-NMR (400 MHz, CDCl3): δ (ppm) = 1.75 (m., 6H), 2.10–2.20 (m, 9H), 3.25–3.39 (s, 3H), 3.77 (t, J = 5.43 Hz, 2H), 4.34 (t, J = 5.43 Hz, 2H), 6.46–6.55 (m, 1H), 6.68–6.78 (m, 1H), 7.39 (s, 1H), 7.40–7.45 (m, 1H), 7.47–7.54 (m, 1H), 7.69 (dd, J = 8.59, 1.77 Hz, 1H), 8.74 (d, J = 1.77 Hz, 1H), 9.01–9.10 (m, 1H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 30.00 (3C), 31.81, 36.43 (3C), 39.23 (3C), 47.15, 59.15, 70.73, 104.46, 110.37, 111.71, 120.26, 138.52, 141.71, 161.32, 181.22. HRMS (ESI+): m/z (%) = 447.5457 (ccd. 447.5455) [M + H]+.
N-(Adamantan-1-yl)-2-(1-(2-(2-fluoroethoxy)ethyl)-5-(furan-2-yl)-1H-indol-3-yl)-2-oxoacetamide (8). This compound was synthesized by employing the same procedure as for compound 7, and it was obtained in 75% yield as yellow solid. 1H-NMR (400 MHz, CDCl3): δ (ppm) = 1.75 (m, 6H), 2.07–2.21 (m, 9H), 3.58–3.66 (m, 1H), 3.66–3.72 (m, 1H), 3.92 (t, J = 5.56 Hz, 2H), 4.38 (t, J = 5.43 Hz, 2H), 4.42–4.48 (m, 1H), 4.52–4.60 (m, 1H), 6.46–6.55 (m, 1H), 6.73 (dd, J = 3.28, 0.76 Hz, 1H), 7.37 (s, 1H), 7.46 (dd, J = 8.59, 0.51 Hz, 1H), 7.50 (dd, J = 1.77, 0.76 Hz, 1H), 7.70 (dd, J = 8.59, 1.77 Hz, 1H), 8.75 (dd, J = 1.64, 0.63 Hz, 1H), 9.07 (s, 1H). 13C-NMR (100 MHz, CDCl3): δ (ppm) = 29.38 (3C), 36.32 (3C), 41.20 (3C), 47.44, 51.79, 69.88, 70.47, 70.67, 82.31, 83.99, 104.39, 110.59, 111.70, 112.25, 118.00, 120.23, 128.21, 135.82, 141.76, 142.14, 154.65, 161.45. HRMS (ESI+): m/z (%) = 479.5627 (ccd. 479.5625) [M + H]+.
4. Conclusions
In this study, the N-alkyl chain of the high affinity and selective CB2 ligand 5 was modified for the possibility of introducing a fluorine atom. The herein developed fluorinated compound 8 retained the high affinity of the lead compound, and will be considered for the development of an 18F-labeled radiotracer for CB2 receptors imaging with PET.
Acknowledgments
This research was supported by DFG fellowship MO 2677/1-1 (R.-P. Moldovan), NIH grant AG037298 (A.G. Horti) and, in part, by Division of Nuclear Medicine of The Johns Hopkins University School of Medicine. We thank Mrs. Tina Spalholz for help with radioligand binding studies, and Dr. Rodrigo Teodoro for scientific discussions.
Abbreviations
| CB2 | cannabinoid receptors type 2 |
| CB1 | cannabinoid receptors type 1 |
| PET | positron emission tomography |
| DMF | N,N-dimethylformamide |
| TBAB | tetrabutylammonium bromide |
| Et3N | triethylamine |
| CHO | Chinese Hamster Ovary |
| EA | ethyl acetate |
| Et2O | diethyl ether |
| DCM | dichloromethane |
| Pd(PPh3)4 | tetrakis(triphenylphosphine)palladium(0) |
| n-BuBr | 1-bromobutane |
| MeI | methyl iodide |
| Hex | hexane |
Supplementary Materials
The 1H NMR spectra of compounds 3, 5, 6, 7 and 8 are available online at http://www.mdpi.com/1420-3049/22/1/77/s1.
Conflicts of Interest
The authors declare no conflict of interest.
References and Notes
Untitled section
References
- 1.Gaoni Y., Mechoulam R. Isolation structure and partial synthesis of active constituent of hashish. J. Am. Chem. Soc. 1964;86:1646–1647. doi: 10.1021/ja01062a046.
- 2.Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003;4:873–884. doi: 10.1038/nrn1247.
- 3.Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 2001;22:565–572. doi: 10.1016/S0165-6147(00)01805-8.
- 4.Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–564. doi: 10.1038/346561a0.
- 5.Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–65. doi: 10.1038/365061a0.
- 6.Hillard C.J. The endocannabinoid signaling system in the CNS: A primer. Int. Rev. Neurobiol. 2015;125:1–47. doi: 10.1016/bs.irn.2015.10.001.
- 7.Hua T., Vemuri K., Pu M., Qu L., Han G.W., Wu Y., Zhao S., Shui W., Li S., Korde A., et al. Crystal structure of the human cannabinoid receptor CB1. Cell. 2016;167:750–762. doi: 10.1016/j.cell.2016.10.004.
- 8.Shao Z., Yin J., Chapman K., Grzemska M., Clark L., Wang J., Rosenbaum D.M. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature. 2016 doi: 10.1038/nature20613.
- 9.Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002;54:161–202. doi: 10.1124/pr.54.2.161.
- 10.Cabral G.A., Ferreira G.A., Jamerson M.J. Endocannabinoids and the immune system in health and disease. Handb. Exp. Pharmacol. 2015;231:185–211. doi: 10.1007/978-3-319-20825-1_6.
- 11.Stella N. Cannabinoid signaling in glial cells. Glia. 2004;48:267–277. doi: 10.1002/glia.20084.
- 12.Palazuelos J., Aguado T., Egia A., Mechoulam R., Guzman M., Galve-Roperh I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006;20:2405–2407. doi: 10.1096/fj.06-6164fje.
- 13.Molina-Holgado E., Vela J.M., Arevalo-Martin A., Almazan G., Molina-Holgado F., Borrell J., Guaza C. Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 2002;22:9742–9753. doi: 10.1523/JNEUROSCI.22-22-09742.2002.
- 14.Maresz K., Carrier E.J., Ponomarev E.D., Hillard C.J., Dittel B.N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem. 2005;95:437–445. doi: 10.1111/j.1471-4159.2005.03380.x.
- 15.Li Y., Kim J. Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus. Neuroscience. 2015;311:253–267. doi: 10.1016/j.neuroscience.2015.10.041.
- 16.Wolfson M.L., Muzzio D.O., Ehrhardt J., Franchi A.M., Zygmunt M., Jensen F. Expression analysis of cannabinoid receptors 1 and 2 in B cells during pregnancy and their role on cytokine production. J. Reprod. Immunol. 2016;116:23–27. doi: 10.1016/j.jri.2016.05.001.
- 17.Eisenstein T.K., Meissler J.J. Effects of cannabinoids on T-cell function and resistance to infection. J. Neuroimmune Pharmacol. 2015;10:204–216. doi: 10.1007/s11481-015-9603-3.
- 18.Bisogno T., Oddi S., Piccoli A., Fazio D., Maccarrone M. Type-2 cannabinoid receptors in neurodegeneration. Pharmacol. Res. 2016;111:721–730. doi: 10.1016/j.phrs.2016.07.021.
- 19.Ashton J.C., Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol. 2007;5:73–80. doi: 10.2174/157015907780866884.
- 20.Turcotte C., Blanchet M.R., Laviolette M., Flamand N. The CB2 receptor and its role as a regulator of inflammation. Cell. Mol. Life Sci. 2016;73:4449–4470. doi: 10.1007/s00018-016-2300-4.
- 21.Benito C., Romero J.P., Tolon R.M., Clemente D., Docagne F., Hillard C.J., Guaza C., Romero J. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci. 2007;27:2396–2402. doi: 10.1523/JNEUROSCI.4814-06.2007.
- 22.Sanchez C., de Ceballos M.L., Gomez del Pulgar T., Rueda D., Corbacho C., Velasco G., Galve-Roperh I., Huffman J.W., Ramon y Cajal S., Guzman M. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res. 2001;61:5784–5789.
- 23.Fernandez-Ruiz J., Romero J., Ramos J.A. Endocannabinoids and neurodegenerative disorders: Parkinson’s Disease, Huntington’s Chorea, Alzheimer’s Disease, and others. Handb. Exp. Pharmacol. 2015;231:233–259. doi: 10.1007/978-3-319-20825-1_8.
- 24.Aizpurua-Olaizola O., Elezgarai I., Rico-Barrio I., Zarandona I., Etxebarria N., Usobiaga A. Targeting the endocannabinoid system: Future therapeutic strategies. Drug. Discov. Today. 2016 doi: 10.1016/j.drudis.2016.08.005.
- 25.Brust P., van den Hoff J., Steinbach J. Development of [18F]-labeled radiotracers for neuroreceptor imaging with positron emission tomography. Neurosci. Bull. 2014;30:777–811. doi: 10.1007/s12264-014-1460-6.
- 26.Horti A.G., Raymont V., Terry G.E. PET imaging of endocannabinoid system. In: Dierckx R.A.J.O., Otte A., de Vries E.F.J., van Waarde A., Luiten P.G.M., editors. PET and SPECT of Neurobiological Systems. Springer; Berlin. Germany: 2014. pp. 249–319.
- 27.Evens N., Bormans G.M. Non-invasive imaging of the type 2 cannabinoid receptor, focus on positron emission tomography. Curr. Top. Med. Chem. 2010;10:1527–1543. doi: 10.2174/156802610793176819.
- 28.Ory D., Celen S., Verbruggen A., Bormans G. PET radioligands for in vivo visualization of neuroinflammation. Curr. Pharm. Des. 2014;20:5897–5913. doi: 10.2174/1381612820666140613120212.
- 29.(a) Ahmad, R.; Postnov, A.; Bormans, G.; Versijpt, J.; Vandenbulcke, M.; van Laere, K. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease. E. J. Nucl. Med. Mol. Imaging 2016, 1–9; (b) Slavik, R.; Muller Herde, A.; Haider, A.; Kramer, S. D.; Weber, M.; Schibli, R.; Ametamey, S.M.; Mu, L. Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2. J. Neurochem. 2016, 874–886; (c) Haider, A.; Müller Herde, A.; Slavik, R.; Weber, M.; Mugnaini, C.; Ligresti, A.; Schibli, R.; Mu, L.; Mensah Ametamey, S. Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor Type 2 Radiotracers for PET Imaging. Front. Neurosci. 2016, 10:350; (d) Slavik, R.; Herde, A.M.; Bieri, D.; Weber, M.; Schibli, R.; Kramer, S.D.; Ametamey, S. M.; Mu, L. Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. Eur. J. Med. Chem. 2015, 92c, 554–564.
- 30.D’Ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., Haycock D.A., Baizman E.R., Casiano F.M. Conformationally restrained analogs of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J. Med. Chem. 1992;35:124–135. doi: 10.1021/jm00079a016.
- 31.Eissenstat M.A., Bell M.R., D’Ambra T.E., Alexander E.J., Daum S.J., Ackerman J.H., Gruett M.D., Kumar V., Estep K.G. Aminoalkylindoles: Structure-activity relationships of novel cannabinoid mimetics. J. Med. Chem. 1995;38:3094–3105. doi: 10.1021/jm00016a013.
- 32.Pasquini S., Mugnaini C., Ligresti A., Tafi A., Brogi S., Falciani C., Pedani V., Pesco N., Guida F., Luongo L., et al. Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: Potent and selective CB2 cannabinoid receptor inverse agonists. J. Med. Chem. 2012;55:5391–5402. doi: 10.1021/jm3003334.
- 33.Aung M.M., Griffin G., Huffman J.W., Wu M.-J., Keel C., Yang B., Showalter V.M., Abood M.E., Martin B.R. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug Alcohol Depend. 2000;60:133–140. doi: 10.1016/S0376-8716(99)00152-0.
- 34.Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 2000;44:235–249. doi: 10.1016/S1056-8719(00)00107-6.
- 35.(a) Moldovan, R.-P.; Teodoro, R.; Gao, Y.; Deuther-Conrad, W.; Kranz, M.; Wang, Y.; Kuwabara, H.; Nakano, M.; Valentine, H.; Fischer, S.; et al. Development of a high-affinity PET radioligand for imaging cannabinoid subtype 2 receptor. J. Med. Chem. 2016, 59, 7840–7855; (b) Savonenko, A.V.; Melnikova, T.; Wang, Y.; Ravert, H.; Gao, Y.; Koppel, J.; Lee, D.; Pletnikova, O.; Cho, E.; Sayyida, N.; et al. Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS ONE 2015, 10, e0129618; (c) Horti, A.G.; Gao, Y.; Ravert, H.T.; Finley, P.; Valentine, H.; Wong, D.F.; Endres, C.J.; Savonenko, A.V.; Dannals, R.F. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg. Med. Chem. 2010, 18, 5202–5207.
- 36.Pasquini S., Mugnaini C., Brizzi A., Ligresti A., di Marzo V., Ghiron C., Corelli F. Rapid Combinatorial Access to a Library of 1,5-Disubstituted-3-indole-N-alkylacetamides as CB2 Receptor Ligands. J. Comb. Chem. 2009;11:795–798. doi: 10.1021/cc9000955.
- 37.Pasquini S., Ligresti A., Mugnaini C., Semeraro T., Cicione L., de Rosa M., Guida F., Luongo L., de Chiaro M., Cascio M.G., et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands. J. Med. Chem. 2010;53:5915–5928. doi: 10.1021/jm100123x.
- 38.Mugnaini C., Brizzi A., Ligresti A., Allarà M., Lamponi S., Vacondio F., Silva C., Mor M., di Marzo V., Corelli F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. J. Med. Chem. 2016;59:1052–1067. doi: 10.1021/acs.jmedchem.5b01559.
- 39.Friscourt F., Fahrni C.J., Boons G.-J. A fluorogenic probe for the catalyst-free detection of azide-tagged molecules. J. Am. Chem. Soc. 2012;134:18809–18815. doi: 10.1021/ja309000s.
- 40.Cui M., Wang X., Yu P., Zhang J., Li Z., Zhang X., Yang Y., Ono M., Jia H., Saji H., et al. Synthesis and evaluation of novel 18F labeled 2-pyridinylbenzoxazole and 2-pyridinylbenzothiazole derivatives as ligands for positron emission tomography (PET) imaging of β-amyloid plaques. J. Med. Chem. 2012;55:9283–9296. doi: 10.1021/jm300973k.
- 41.Williamson A. XLV. Theory of ætherification. Philos. Mag. Ser. 1850;37:350–356.
- 42.Rühl T., Deuther-Conrad W., Fischer S., Günther R., Hennig L., Krautscheid H., Brust P. Cannabinoid receptor type 2 (CB2)-selective N-aryl-oxadiazolyl-propionamides: Synthesis, radiolabelling, molecular modelling and biological evaluation. Org. Med. Chem. Lett. 2012;2:32. doi: 10.1186/2191-2858-2-32.
- 43.Teodoro R., Moldovan R.-P., Lueg C., Günther R., Donat C.K., Ludwig F.-A., Fischer S., Deuther-Conrad W., Wünsch B., Brust P. Radiofluorination and biological evaluation of N-aryl-oxadiazolyl-propionamides as potential radioligands for PET imaging of cannabinoid CB2 receptors. Org. Med. Chem. Lett. 2013;3:1–18. doi: 10.1186/2191-2858-3-11.
- 44.Yung-Chi C., Prusoff W.H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973;22:3099–3108. doi: 10.1016/0006-2952(73)90196-2.